Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory A Masters

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab GovitecanJhanelle E Gray, Rebecca S Heist, Alexander N Starodub, et al.
Journal for Immunotherapy of Cancer|June 26, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJulie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, et al.
Cancer Research Communications|July 27, 2023
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 BenefitBenjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab GovitecanJhanelle E Gray, Rebecca S Heist, Alexander N Starodub, et al.
Journal for Immunotherapy of Cancer|June 26, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJulie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, et al.
Cancer Research Communications|July 27, 2023
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 BenefitBenjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, et al.
Pageof 5